Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03037931 · ClinicalTrials.gov registry record · Phase 3
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,065
- Enrollment target
NCT03037931: Completed Phase 3 study, sponsored by American Regent.
NCT03037931 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 3,065 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (297% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03037931, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,065 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
Primary Outcome
The number of participants who died out of the total treated group.
Interventions
- DRUG Placebo
- DRUG Ferric Carboxymaltose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,065 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 3 |
What the finished NCT03037931 record still lists
NCT03037931 is an interventional study that assigns participants to a tested intervention. Its 3,065 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (297% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03037931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03037931 about?
NCT03037931 is a clinical study titled "Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study". The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency
What is the current status of trial NCT03037931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,065 participants. The study started on 2017-03-15. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT03037931?
The interventions under investigation include: Placebo (DRUG), Ferric Carboxymaltose (DRUG).
Who is sponsoring clinical trial NCT03037931?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03037931's enrollment target sits among peer trials
3,065 77th of 2000 higher than 1,924 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI